LY3361237

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY3361237, covering 2025-01-20 to 2025-01-20. Get the full timeline:

Most recent: Clinical Trial Update: A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus [Phase 2]

See pricing